Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers
- 24 September 2020
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 55 (12) , 3400-3406
Abstract
Introduction: Oral antibiotics are frequently prescribed for outpatient pulmonary exacerbations (PEx) in children with cystic fibrosis (CF). This study aimed to characterize oral antibiotic use for PEx and treatment outcomes at two large US CF centers.Methods: Retrospective, descriptive study of oral antibiotic prescribing practices among children with CF ages 6–17 years over 1 year. The care setting for antibiotic initiation (clinic or phone encounter) was determined and outcomes were compared.Results: A total of 763 oral antibiotic courses were prescribed to 312 patients aged 6–17 years (77% of 403 eligible patients) with a median of two courses per year (range: 1–10). Fifty‐eight percent of prescriptions were provided over the phone. Penicillin was the most commonly prescribed antibiotic class (36% of prescriptions) but differences in antibiotic class prescriptions were noted between the two centers. Hospitalizations occurred within 3 months following 19% of oral antibiotic courses. Forced expiratory volume in 1 s (FEV1) recovered to within 90% of prior baseline within 6 months in 87% of encounters; the mean (SD) % recovery was 99.6% (12.1%) of baseline. Outcomes did not differ between phone and clinic prescriptions.Conclusions: Phone prescriptions, commonly excluded in studies of PEx, made up more than half of all oral antibiotic courses. Heterogeneity in prescribing patterns was observed between the two centers. Most patients had improvement in FEV1 returning to near their prior baseline, but hospitalizations occurred in one‐fifth following oral antibiotic treatment. Efforts to optimize PEx treatment must consider care that occurs over the phone; this is particularly important as the use of telemedicine increases.Keywords
Funding Information
- Cystic Fibrosis Foundation (HOPPE16A0, SANDERS18A1)
This publication has 22 references indexed in Scilit:
- Predictors of pulmonary exacerbation treatment in cystic fibrosisJournal of Cystic Fibrosis, 2020
- Impact of a program ensuring consistent response to acute drops in lung function in children with cystic fibrosisJournal of Cystic Fibrosis, 2018
- Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosisJournal of Cystic Fibrosis, 2018
- Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosisThorax, 2016
- Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesiaEuropean Respiratory Journal, 2015
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosisPediatric Pulmonology, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single‐center experienceThe Clinical Respiratory Journal, 2011